Literature DB >> 21228325

Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice.

Li Li1, Li Zhang, Jinshui Fan, Kathleen Greenberg, Stephen Desiderio, Feyruz V Rassool, Donald Small.   

Abstract

We have generated an FLT3/ITD knock-in mouse model in which mice with an FLT3/ITD mutation develop myeloproliferative disease (MPD) and a block in early B-lymphocyte development. To elucidate the role of FLT3/ITD signaling in B-cell development, we studied VDJ recombination in the pro-B cells of FLT3/ITD mice and discovered an increased frequency of DNA double strand breaks (DSBs) introduced by the VDJ recombinase. Early pro-B cells from FLT3/ITD mice were found to have a lower efficiency and decreased accuracy of DSB repair by nonhomologous end joining (NHEJ), which is required for rejoining DSBs during VDJ recombination. Reduced NHEJ repair probably results from reduced expression of Ku86, a key component of the classic DNA-PK-dependent NHEJ pathway. In compensation, early pro-B cells from FLT3/ITD cells mice show increased levels of the alternative, and highly error-prone, NHEJ pathway protein PARP1, explaining the increase in repair errors. These data suggest that, in early pro-B cells from FLT3/ITD mice, impairment of classic NHEJ decreases the ability of cells to complete postcleavage DSB ligation, resulting in failure to complete VDJ recombination and subsequent block of B-lymphocyte maturation. These findings might explain the poor prognosis of leukemia patients with constitutive activation of FLT3 signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228325      PMCID: PMC3062315          DOI: 10.1182/blood-2010-05-286070

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair.

Authors:  J R Walker; R A Corpina; J Goldberg
Journal:  Nature       Date:  2001-08-09       Impact factor: 49.962

2.  Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations.

Authors:  Chengming Zhu; Kevin D Mills; David O Ferguson; Charles Lee; John Manis; James Fleming; Yijie Gao; Cynthia C Morton; Frederick W Alt
Journal:  Cell       Date:  2002-06-28       Impact factor: 41.582

3.  Identification of CD19(-)B220(+)c-Kit(+)Flt3/Flk-2(+)cells as early B lymphoid precursors before pre-B-I cells in juvenile mouse bone marrow.

Authors:  M Ogawa; E ten Boekel; F Melchers
Journal:  Int Immunol       Date:  2000-03       Impact factor: 4.823

Review 4.  V(D)J recombination: RAG proteins, repair factors, and regulation.

Authors:  Martin Gellert
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

5.  Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity.

Authors:  J Adolfsson; O J Borge; D Bryder; K Theilgaard-Mönch; I Astrand-Grundström; E Sitnicka; Y Sasaki; S E Jacobsen
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

6.  Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.

Authors:  Jinshui Fan; Li Li; Donald Small; Feyruz Rassool
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

Review 7.  FLT3: ITDoes matter in leukemia.

Authors:  M Levis; D Small
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

8.  Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress.

Authors:  Istvan Boldogh; Gargi Roy; Myung Soog Lee; Attila Bacsi; Tapas K Hazra; Kishor K Bhakat; Gokul C Das; Sankar Mitra
Journal:  Toxicology       Date:  2003-11-15       Impact factor: 4.221

Review 9.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

10.  Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk.

Authors:  Theresa Tretter; Ashley E Ross; Dominic I Dordai; Stephen Desiderio
Journal:  J Exp Med       Date:  2003-12-08       Impact factor: 14.307

View more
  13 in total

1.  FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

Authors:  Hayley S Ma; Bao Nguyen; Amy S Duffield; Li Li; Allison Galanis; Allen B Williams; Patrick A Brown; Mark J Levis; Daniel J Leahy; Donald Small
Journal:  Cancer Res       Date:  2014-07-24       Impact factor: 12.701

2.  TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

Authors:  Hayley Ma; Bao Nguyen; Li Li; Sarah Greenblatt; Allen Williams; Ming Zhao; Mark Levis; Michelle Rudek; Amy Duffield; Donald Small
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 3.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

4.  c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Authors:  Nidal Muvarak; Shannon Kelley; Carine Robert; Maria R Baer; Danilo Perrotti; Carlo Gambacorti-Passerini; Curt Civin; Kara Scheibner; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2015-03-31       Impact factor: 5.852

Review 5.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

6.  FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.

Authors:  Emily Bailey; Li Li; Amy S Duffield; Hayley S Ma; David L Huso; Don Small
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-19       Impact factor: 11.205

7.  The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Authors:  Liang Zhou; Shuang Chen; Yu Zhang; Maciej Kmieciak; Yun Leng; Lihong Li; Hui Lin; Kathryn A Rizzo; Catherine I Dumur; Andrea Ferreira-Gonzalez; Mohamed Rahmani; Lawrence Povirk; Sri Chalasani; Allison J Berger; Yun Dai; Steven Grant
Journal:  Blood       Date:  2016-02-05       Impact factor: 22.113

8.  Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.

Authors:  Li Li; Emily Bailey; Sarah Greenblatt; David Huso; Donald Small
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

9.  FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.

Authors:  S Haihua Chu; Diane Heiser; Li Li; Ian Kaplan; Michael Collector; David Huso; Saul J Sharkis; Curt Civin; Don Small
Journal:  Cell Stem Cell       Date:  2012-09-07       Impact factor: 24.633

10.  FLT3 in lineage specification and plasticity.

Authors:  Sarah Greenblatt; Donald Small
Journal:  Oncotarget       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.